Gene Logic Establishes Genomic Database Agreement with Aventis Pharmaceuticals

14-Dec-2001

Gene Logic Inc. (Nasdaq:GLGC - news), a leading provider of biocontent and bioinformatics solutions, today announced the establishment of a genomic database agreement with Aventis Pharmaceuticals Inc., the U.S. pharmaceuticals division of Frankfurt, Germany-based Aventis Pharma AG, the global pharmaceutical company of Aventis SA (NYSE:AVE - news). Financial details of the database agreement were not disclosed. Under terms of the agreement, Aventis will establish a CustomSuite subscription, gaining access to a customized selection of biosamples across a specific group of organ types culled directly from the BioExpress(TM) Module of Gene Logic's comprehensive gene expression database, the GeneExpress® Suite. The CustomSuite database product is designed to provide Aventis researchers with a baseline reference source of normal and diseased gene expression data for areas with direct application in Aventis' therapeutic target selection, screening and prioritization initiatives. The agreement also calls for proprietary data to be generated from samples provided by Aventis. These data will be integrated with the Gene Logic data in their CustomSuite data product. The resulting combined database tool will be housed within Gene Logic's comprehensive bioinformatics interface, the GeneExpress® software System, which will enable Aventis researchers to quickly and efficiently index, mine, analyze and visualize the vast amounts of resulting genomic data. This tool will be accessed by researchers spanning Aventis' global research and development infrastructure.

``We are extremely pleased to initiate a business relationship with Aventis Pharmaceuticals through their subscription to our GeneExpress® database product,'' commented David S. Murray, Senior Vice President, Marketing and Sales for Gene Logic. ``Aventis is a premier global pharmaceutical company looking to improve the efficiency of its drug discovery pipeline through adoption of new genomic technologies. Our goal is to provide them with the latest emerging research capabilities to enable and support Aventis and its researchers in their ongoing efforts to achieve their drug discovery and development goals.''

https://www.chemeurope.com/en/news/6650/gene-logic-establishes-genomic-database-agreement-with-aventis-pharmaceuticals.html